Type of information: Nomination
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
- • On June 28, 2017, Sarepta Therapeutics announced the appointment of Douglas S. Ingram as president and chief executive officer. He will also serve on the Company’s board of directors. As previously announced, Edward M. Kaye will step down from his positions at the Company, but is expected to serve the Company in an advisory capacity to ensure a smooth transition.
- Until its acquisition by Actavis in 2015, Mr. Ingram was the president of Allergan. Prior to his election as president, Mr. Ingram was located in London as Allergan’s president Europe/Middle East/Africa and before that ran various functions at Allergan, including Legal Affairs, Regulatory Affairs and Pharmacovigilance, Information Technology, Public Relations and External Communication, Human Resources, and Audit and Compliance, among others.
- Most recently, Mr. Ingram served as president and chief executive officer of Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on new treatments for neurodegenerative disorders, which was acquired by Allergan, in late 2016. He graduated Magna Cum Laude from Arizona State University with a Bachelor of Science degree and Summa Cum Laude from the University of Arizona, James E. Rogers College of Law.